Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

In the trial, Dupixent® (dupilumab) outperformed Xolair® (omalizumab ... Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the EVEREST Phase 4 trial in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and ...

In the trial, Dupixent ® (dupilumab) outperformed Xolair ® (omalizumab ... Dupixent, which was invented using Regeneron's proprietary VelocImmune ® technology, is a fully human monoclonal ...

“EVEREST is the first-ever trial to demonstrate the superiority ... In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases ...

New findings from the EVEREST Phase 4 trial presented at the 2025 EAACI Congress reveal that Dupixent (dupilumab ... 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...

GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, ...